Th e aim of this trial was to examine the effi cacy and safety of antihypertensive fi xed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension. In our trial we included  patients, aged ,±, years, with treated or untreated hypertension and with high risk of cardiac events, in an opened trial of therapy based on lisinopril plus hydrochlorothiazide. Upon the examination by physicians, patients were divided into three groups in accordance with European Society of Cardiology guidelines for the management of arterial hypertension. Patients from fi ve European countries were followed up for a period of  weeks. Duration of treatment was  weeks. We adjusted daily doses of lisinopril plus hydrochlorothiazide after every clinical examination and recorded adverse eff ects of drugs. After  weeks of treatment,  patients () were evaluated for effi cacy, tolerability and safety. In almost , patients with mild, moderate and severe hypertension , we recorded a reduction in blood pressure to approximately normal values SBP and DBP (/ mmHg). Drug-related side-eff ects occurred in  patients (,). Th e most commonly reported adverse eff ects associated with lisinopril plus hydrochlorothiazide were cough () and dry mouth (). Th is research has proved good effi cacy of fi xed combination lisinopril plus hydrochlorothiazide with more than  patients. Based on subjective estimation by patients: this drug improved quality of life in all cases.
Introduction
High arterial pressure is probably the most important public health problem in developed countries. Th at is frequently asymptomatic condition that is easily discovered and it is mostly cured in simple manner, but it might lead to severe and fatal complications often if not treated on time, suffi ciently and adequately. It is estimated that around billion people have hypertension, and that this number will be increased by  until , i.e. it shall amount to a billion and  million at that moment. Essential hypertension is nowadays by far the most important risk factor in appearance of cardiovascular diseases. A range of studies that were conducted in last couple of decades, starting from Framingham study onwards, undoubtedly tell in favour of the fact that effi cient treatment of high arterial pressure might prevent complications on target organs, or, if nothing else, to move them from such a life period when patients are at peak of their intellectual and production capabilities, what is of enormous value for social structure of each society.
Objective
The aim of this trial was to examine the efficacy and safety of antihypertensive fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension.
Patients and Methods
The trial was open, multi-centre, prospective, clinical trial lasting  weeks per patient. Totally  subjects with essential hypertension were included in the trial, of I-III degree, both genders aged  to  years. On the basis of average values of three independent measurements of blood pressure (BP) (the same physician, the same measuring apparatus) were divided into three groups First group -Patients with essential hypertension of fi rst degree (Mild hypertension) (BP -/- mmHg). Second group -Patients with essential hypertension of second degree (Moderate hypertension) (BP -/  - mmHg) Th ird group -Patients with essential hypertension of third degree (Severe hypertension) (BP above / mmHg) Total duration of the trial per patient was  weeks. Th e following examinations and measurings were performed prior to including into trial: . Blood pressure and pulse . Electrocardiogram (Sokolow -Lyons; Cornell) . Echocardiography (of heart obligatory LVMI -left ventricle mass index) . Ultrasound of carotid arteries -(thickness of the wall and attention directed at arterioslerotic plaques) . X-rays of the chest . Eye fundus examination Average age of all patients included into trial was ,±, years, and  women and  men were included into trial. On the basis of initial results of blood pressure, the patients were classifi ed in one of the following groups on basis of severity of hypertension, according to European Classification of Hypertension () () ences between the groups by gender and age. Average duration of illness for all patients was around ,±, years, and duration of illness was very similar among the groups (Table ) .
In the beginning of trial, we estimated also risk factors, so that smoking, increased body weight and heredity were equally distributed in the groups and no signifi cant differences were reported between the risk factors (Table ) . In addition to high blood pressure, increased body weight (body mass index ,-, ) was present in  women and , men, and obesity (body mass index above ) was present in , women and  men, so that completely , women and , men had optimal body weight. Statistical processing of results Statistical analyses were made in statistical programme MedCalc for Windows, version ... (MedCalc Software, Mariakerke, Belgium). Results are shown through the usual descriptive statistics. As an estimate of significance of differences between the average measuring, significance was taken of p<,.
Methods
Th e study was done in compliance with Guidelines for Good Clinical Practice and Declaration Helsinki () of the World Medical Association and all patients provided written informed consent before the start of the study. This -week opened prospective clinical trial was done at  centres in fi ve European countries. After  weeks washout period for patients receiving antihypertensive medications, patients entered in study. Upon the examination by physicians, patients were divided into three groups in accordance with European Society of Cardiology guidelines for the management of arterial hypertension. Patients were followed up for period of  weeks and duration of treatment was  weeks. We adjusted daily doses of lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek) after every clinical examination and recorded adverse eff ects of drugs.
Results
Total number of  patients (ITT) were included in the trial,  patients completely fi nalised the trial (by trial protocol, PP, ), and  patients did not finish the study (). Reasons for giving up of trial are not related to side-eff ects of drugs, nor intolerance to medicines, but they are linked to patients' non-cooperation in the trial (e.g. irregular coming to control check-ups and irregular administration of therapy) ( Table ) . In Table  differences in values of blood pressure We made analysis for all included patients (n=) in the trial, and average lowering was accomplished for sys/dia BP ,mmHg/,mmHg, or by ,/, (Figure ) .
Analysis of results has shown that we obtained the best results in medication's eff ect on the systolic blood pressure, where lowering was accomplished in all the groups from , to ,, while diff erences between baseline and fi nal values of diastolic blood pressure by groups were from , to , ( Figure  ,,) .
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Discussion
Despite the availability of over  diff erent antihypertensive agents in  diff erent classes, an estimated  of treated patients in the United States remain uncontrolled in . , ,  Th e lack of control of hypertension is of particular concern in patients with coexisting cardiovascular disorders. To reduce this unacceptably high rate of prior control, most patients will require combination therapies, as noted in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC ) ( ) . In our trial we used fixed combination of two antihypertensives lisinopril and hydrohlorthiazid (Lopril H, Bosnalijek) . The efficacy can be seen in the reduction of systolic and diastolic pressure, and in the great number of patients (,), the control of blood pressure under / mmHg has been achieved. Many older studies utilized diastolic blood pressure to guide therapy, systolic blood pressure control is even more important (,,,) . For example, among patients with stage  hypertension, a sustained  mm Hg decrease in systolic blood pressure for  years will prevent  death for every  treated patients who have diabetes mellitus or cardiovascular disease. Furthermore, even small reductions in systolic blood pressure ( mm Hg to  mm Hg) produce dramatic reductions in events such as heart failure and stroke (,) . Controlling the systolic blood pressure is critical, as demonstrated in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) () . Despite a design that should have led to similar control in all groups (chlorthalidone, amlodipine, or lisinopril) over  to  years, systolic blood pressure remained significantly higher in the lisinopril group than in the diuretic control group throughout the study. The higher rate of stroke in the lisinopril group compared with the chlorthalidone group was most likely a manifestation of this poor control. Th e importance of controlling the systolic blood pressure early was demonstrated in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial () , which hypothesized that angiotensin blockade would be superior to calcium antagonism. Although both treatments reduced blood pressure, the eff ects of the amlodipine regimen on systolic blood pressure were more pronounced, especially in the fi rst year of the study. Th e -year results showed no diff erence in the primary endpoint of time to a fi rst cardiac event, but there was a signifi cant increase in fatal and nonfatal myocardial infarction in the valsartan group, particularly in the fi rst year of the study when systolic blood pressure control favored amlodipine. Of interest is that more patients developed heart failure on amlodipine compared with valsartan, despite better blood pressure control with amlodipine () . We recorded excellent efficacy in the reduction of systolic and diastolic blood pressure in , of patients for systolic blood pressure (reduction for - mmHg and higher) and , for diastolic blood pressure (reduction for - mm Hg and higher).
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